1.Comparison of the Data of a Next-Generation Sequencing Panel from K-MASTER Project with That of Orthogonal Methods for Detecting Targetable Genetic Alterations
Yoon Ji CHOI ; Jung Yoon CHOI ; Ju Won KIM ; Ah Reum LIM ; Youngwoo LEE ; Won Jin CHANG ; Soohyeon LEE ; Jae Sook SUNG ; Hee-Joon CHUNG ; Jong Won LEE ; Eun Joo KANG ; Jung Sun KIM ; Taekyu LIM ; Hye Sook KIM ; Yu Jung KIM ; Mi Sun AHN ; Young Saing KIM ; Ji Hyun PARK ; Seungtaek LIM ; Sung Shim CHO ; Jang Ho CHO ; Sang Won SHIN ; Kyong Hwa PARK ; Yeul Hong KIM
Cancer Research and Treatment 2022;54(1):30-39
Purpose:
K-MASTER project is a Korean national precision medicine platform that screened actionable mutations by analyzing next-generation sequencing (NGS) of solid tumor patients. We compared gene analyses between NGS panel from the K-MASTER project and orthogonal methods.
Materials and Methods:
Colorectal, breast, non–small cell lung, and gastric cancer patients were included. We compared NGS results from K-MASTER projects with those of non-NGS orthogonal methods (KRAS, NRAS, and BRAF mutations in colorectal cancer [CRC]; epidermal growth factor receptor [EGFR], anaplastic lymphoma kinase [ALK] fusion, and reactive oxygen species 1 [ROS1] fusion in non–small cell lung cancer [NSCLC], and Erb-B2 receptor tyrosine kinase 2 (ERBB2) positivity in breast and gastric cancers).
Results:
In the CRC cohort (n=225), the sensitivity and specificity of NGS were 87.4% and 79.3% (KRAS); 88.9% and 98.9% (NRAS); and 77.8% and 100.0% (BRAF), respectively. In the NSCLC cohort (n=109), the sensitivity and specificity of NGS for EGFR were 86.2% and 97.5%, respectively. The concordance rate for ALK fusion was 100%, but ROS1 fusion was positive in only one of three cases that were positive in orthogonal tests. In the breast cancer cohort (n=260), ERBB2 amplification was detected in 45 by NGS. Compared with orthogonal methods that integrated immunohistochemistry and in situ hybridization, sensitivity and specificity were 53.7% and 99.4%, respectively. In the gastric cancer cohort (n=64), ERBB2 amplification was detected in six by NGS. Compared with orthogonal methods, sensitivity and specificity were 62.5% and 98.2%, respectively.
Conclusion
The results of the K-MASTER NGS panel and orthogonal methods showed a different degree of agreement for each genetic alteration, but generally showed a high agreement rate.
2.Clinical practice guideline for endoscopic resection of early gastrointestinal cancer
Chan Hyuk PARK ; Dong-Hoon YANG ; Jong Wook KIM ; Jie-Hyun KIM ; Ji Hyun KIM ; Yang Won MIN ; Si Hyung LEE ; Jung Ho BAE ; Hyunsoo CHUNG ; Kee Don CHOI ; Jun Chul PARK ; Hyuk LEE ; Min-Seob KWAK ; Bun KIM ; Hyun Jung LEE ; Hye Seung LEE ; Miyoung CHOI ; Dong-Ah PARK ; Jong Yeul LEE ; Jeong-Sik BYEON ; Chan Guk PARK ; Joo Young CHO ; Soo Teik LEE ; Hoon Jai CHUN
Intestinal Research 2021;19(2):127-157
Although surgery was the standard treatment for early gastrointestinal cancers, endoscopic resection is now a standard treatment for early gastrointestinal cancers without regional lymph node metastasis. High-definition white light endoscopy, chromoendoscopy, and image-enhanced endoscopy such as narrow band imaging are performed to assess the edge and depth of early gastrointestinal cancers for delineation of resection boundaries and prediction of the possibility of lymph node metastasis before the decision of endoscopic resection. Endoscopic mucosal resection and/or endoscopic submucosal dissection can be performed to remove early gastrointestinal cancers completely by en bloc fashion. Histopathological evaluation should be carefully made to investigate the presence of risk factors for lymph node metastasis such as depth of cancer invasion and lymphovascular invasion. Additional treatment such as radical surgery with regional lymphadenectomy should be considered if the endoscopically resected specimen shows risk factors for lymph node metastasis. This is the first Korean clinical practice guideline for endoscopic resection of early gastrointestinal cancer. This guideline was developed by using mainly de novo methods and encompasses endoscopic management of superficial esophageal squamous cell carcinoma, early gastric cancer, and early colorectal cancer. This guideline will be revised as new data on early gastrointestinal cancer are collected.
3.Clinical practice guideline for endoscopic resection of early gastrointestinal cancer
Chan Hyuk PARK ; Dong-Hoon YANG ; Jong Wook KIM ; Jie-Hyun KIM ; Ji Hyun KIM ; Yang Won MIN ; Si Hyung LEE ; Jung Ho BAE ; Hyunsoo CHUNG ; Kee Don CHOI ; Jun Chul PARK ; Hyuk LEE ; Min-Seob KWAK ; Bun KIM ; Hyun Jung LEE ; Hye Seung LEE ; Miyoung CHOI ; Dong-Ah PARK ; Jong Yeul LEE ; Jeong-Sik BYEON ; Chan Guk PARK ; Joo Young CHO ; Soo Teik LEE ; Hoon Jai CHUN
Intestinal Research 2021;19(2):127-157
Although surgery was the standard treatment for early gastrointestinal cancers, endoscopic resection is now a standard treatment for early gastrointestinal cancers without regional lymph node metastasis. High-definition white light endoscopy, chromoendoscopy, and image-enhanced endoscopy such as narrow band imaging are performed to assess the edge and depth of early gastrointestinal cancers for delineation of resection boundaries and prediction of the possibility of lymph node metastasis before the decision of endoscopic resection. Endoscopic mucosal resection and/or endoscopic submucosal dissection can be performed to remove early gastrointestinal cancers completely by en bloc fashion. Histopathological evaluation should be carefully made to investigate the presence of risk factors for lymph node metastasis such as depth of cancer invasion and lymphovascular invasion. Additional treatment such as radical surgery with regional lymphadenectomy should be considered if the endoscopically resected specimen shows risk factors for lymph node metastasis. This is the first Korean clinical practice guideline for endoscopic resection of early gastrointestinal cancer. This guideline was developed by using mainly de novo methods and encompasses endoscopic management of superficial esophageal squamous cell carcinoma, early gastric cancer, and early colorectal cancer. This guideline will be revised as new data on early gastrointestinal cancer are collected.
4.Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer
Chan Hyuk PARK ; Dong-Hoon YANG ; Jong Wook KIM ; Jie-Hyun KIM ; Ji Hyun KIM ; Yang Won MIN ; Si Hyung LEE ; Jung Ho BAE ; Hyunsoo CHUNG ; Kee Don CHOI ; Jun Chul PARK ; Hyuk LEE ; Min-Seob KWAK ; Bun KIM ; Hyun Jung LEE ; Hye Seung LEE ; Miyoung CHOI ; Dong-Ah PARK ; Jong Yeul LEE ; Jeong-Sik BYEON ; Chan Guk PARK ; Joo Young CHO ; Soo Teik LEE ; Hoon Jai CHUN
Journal of Digestive Cancer Report 2020;8(1):1-50
Although surgery was the standard treatment for early gastrointestinal cancers, endoscopic resection is now a standard treatment for early gastrointestinal cancers without regional lymph node metastasis. High-definition white light endoscopy, chromoendoscopy, and image-enhanced endoscopy such as narrow band imaging are performed to assess the edge and depth of early gastrointestinal cancers for delineation of resection boundaries and prediction of the possibility of lymph node metastasis before the decision of endoscopic resection. Endoscopic mucosal resection and/or endoscopic submucosal dissection can be performed to remove early gastrointestinal cancers completely by en bloc fashion. Histopathological evaluation should be carefully made to investigate the presence of risk factors for lymph node metastasis such as depth of cancer invasion and lymphovascular invasion. Additional treatment such as radical surgery with regional lymphadenectomy should be considered if the endoscopically resected specimen shows risk factors for lymph node metastasis. This is the first Korean clinical practice guideline for endoscopic resection of early gastrointestinal cancer. This guideline was developed by using mainly de novo methods and encompasses endoscopic management of superficial esophageal squamous cell carcinoma, early gastric cancer, and early colorectal cancer. This guideline will be revised as new data on early gastrointestinal cancer are collected.
5.cal Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer
Chan Hyuk PARK ; Dong-Hoon YANG ; Jong Wook KIM ; Jie-Hyun KIM ; Ji Hyun KIM ; Yang Won MIN ; Si Hyung LEE ; Jung Ho BAE ; Hyunsoo CHUNG ; Kee Don CHOI ; Jun Chul PARK ; Hyuk LEE ; Min-Seob KWAK ; Bun KIM ; Hyun Jung LEE ; Hye Seung LEE ; Miyoung CHOI ; Dong-Ah PARK ; Jong Yeul LEE ; Jeong-Sik BYEON ; Chan Guk PARK ; Joo Young CHO ; Soo Teik LEE ; Hoon Jai CHUN
The Korean Journal of Gastroenterology 2020;75(5):264-291
Although surgery was the standard treatment for early gastrointestinal cancers, endoscopic resection is now a standard treatment for early gastrointestinal cancers without regional lymph node metastasis. High-definition white light endoscopy, chromoendoscopy, and image-enhanced endoscopy such as narrow band imaging are performed to assess the edge and depth of early gastrointestinal cancers for delineation of resection boundaries and prediction of the possibility of lymph node metastasis before the decision of endoscopic resection. Endoscopic mucosal resection and/or endoscopic submucosal dissection can be performed to remove early gastrointestinal cancers completely by en bloc fashion. Histopathological evaluation should be carefully made to investigate the presence of risk factors for lymph node metastasis such as depth of cancer invasion and lymphovascular invasion. Additional treatment such as radical surgery with regional lymphadenectomy should be considered if the endoscopically resected specimen shows risk factors for lymph node metastasis. This is the first Korean clinical practice guideline for endoscopic resection of early gastrointestinal cancer. This guideline was developed by using mainly de novo methods and encompasses endoscopic management of superficial esophageal squamous cell carcinoma, early gastric cancer, and early colorectal cancer. This guideline will be revised as new data on early gastrointestinal cancer are collected.
6.Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer
Chan Hyuk PARK ; Dong-Hoon YANG ; Jong Wook KIM ; Jie-Hyun KIM ; Ji Hyun KIM ; Yang Won MIN ; Si Hyung LEE ; Jung Ho BAE ; Hyunsoo CHUNG ; Kee Don CHOI ; Jun Chul PARK ; Hyuk LEE ; Min-Seob KWAK ; Bun KIM ; Hyun Jung LEE ; Hye Seung LEE ; Miyoung CHOI ; Dong-Ah PARK ; Jong Yeul LEE ; Jeong-Sik BYEON ; Chan Guk PARK ; Joo Young CHO ; Soo Teik LEE ; Hoon Jai CHUN
The Korean Journal of Helicobacter and Upper Gastrointestinal Research 2020;20(2):117-145
Although surgery was the standard treatment for early gastrointestinal cancers, endoscopic resection is now a standard treatment for early gastrointestinal cancers without regional lymph node metastasis. High-definition white light endoscopy, chromoendoscopy, and image-enhanced endoscopy such as narrow band imaging are performed to assess the edge and depth of early gastrointestinal cancers for delineation of resection boundaries and prediction of the possibility of lymph node metastasis before the decision of endoscopic resection. Endoscopic mucosal resection and/or endoscopic submucosal dissection can be performed to remove early gastrointestinal cancers completely by en bloc fashion. Histopathological evaluation should be carefully made to investigate the presence of risk factors for lymph node metastasis such as depth of cancer invasion and lymphovascular invasion. Additional treatment such as radical surgery with regional lymphadenectomy should be considered if the endoscopically resected specimen shows risk factors for lymph node metastasis. This is the first Korean clinical practice guideline for endoscopic resection of early gastrointestinal cancer. This guideline was developed by using mainly de novo methods and encompasses endoscopic management of superficial esophageal squamous cell carcinoma, early gastric cancer, and early colorectal cancer. This guideline will be revised as new data on early gastrointestinal cancer are collected.
7.Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer
Chan Hyuk PARK ; Dong-Hoon YANG ; Jong Wook KIM ; Jie-Hyun KIM ; Ji Hyun KIM ; Yang Won MIN ; Si Hyung LEE ; Jung Ho BAE ; Hyunsoo CHUNG ; Kee Don CHOI ; Jun Chul PARK ; Hyuk LEE ; Min-Seob KWAK ; Bun KIM ; Hyun Jung LEE ; Hye Seung LEE ; Miyoung CHOI ; Dong-Ah PARK ; Jong Yeul LEE ; Jeong-Sik BYEON ; Chan Guk PARK ; Joo Young CHO ; Soo Teik LEE ; Hoon Jai CHUN
Journal of Digestive Cancer Report 2020;8(1):1-50
Although surgery was the standard treatment for early gastrointestinal cancers, endoscopic resection is now a standard treatment for early gastrointestinal cancers without regional lymph node metastasis. High-definition white light endoscopy, chromoendoscopy, and image-enhanced endoscopy such as narrow band imaging are performed to assess the edge and depth of early gastrointestinal cancers for delineation of resection boundaries and prediction of the possibility of lymph node metastasis before the decision of endoscopic resection. Endoscopic mucosal resection and/or endoscopic submucosal dissection can be performed to remove early gastrointestinal cancers completely by en bloc fashion. Histopathological evaluation should be carefully made to investigate the presence of risk factors for lymph node metastasis such as depth of cancer invasion and lymphovascular invasion. Additional treatment such as radical surgery with regional lymphadenectomy should be considered if the endoscopically resected specimen shows risk factors for lymph node metastasis. This is the first Korean clinical practice guideline for endoscopic resection of early gastrointestinal cancer. This guideline was developed by using mainly de novo methods and encompasses endoscopic management of superficial esophageal squamous cell carcinoma, early gastric cancer, and early colorectal cancer. This guideline will be revised as new data on early gastrointestinal cancer are collected.
8.Evaluation of Submucosal or Lymphovascular Invasion Detection Rates in Early Gastric Cancer Based on Pathology Section Interval
Young-Il KIM ; Myeong-Cherl KOOK ; Jee Eun CHOI ; Jong Yeul LEE ; Chan Gyoo KIM ; Bang Wool EOM ; Hong Man YOON ; Keun Won RYU ; Young-Woo KIM ; Il Ju CHOI
Journal of Gastric Cancer 2020;20(2):165-175
Purpose:
The guidelines for pathological evaluation of early gastric cancer (EGC) recommend wider section intervals for surgical specimens (5–7 mm) than those for endoscopically resected specimens (2–3 mm). Studies in surgically resected EGC specimens showed not negligible lymph node metastasis risks in EGCs meeting the expanded criteria for endoscopic submucosal dissection (ESD).
Materials and Methods:
This retrospective study included 401 EGC lesions with an endoscopic size of ≤ 30 mm detected in 386 patients. Pathological specimens obtained by ESD or surgery were cut into 2-mm section intervals for reference. Submucosal or lymphovascular invasion (LVI) was evaluated arbitrarily in 4- or 6-mm section intervals. McNemar's tests compared the differences between submucosal and LVI.
Results:
Submucosal invasion was detected in 29.2% (117/401) and LVI in 9.5% (38/401) at 2-mm interval. The submucosal invasion detection rates in 4-mm intervals decreased to 88.0% or 90.6% (both P<0.001), while the LVI detection rates decreased to 86.8% or 57.9% (P=0.025 and P<0.001, respectively). In 6-mm intervals, the submucosal and LVI detection rates decreased further to 72.7–80.3% (P<0.001 for all three sets) and 55.3–63.2% (P<0.001 for all three sets), respectively. Among 150 out-of-indication cases at 2-mm interval, 4–10 (2.7%–6.7%) at 4-mm intervals, and 10–17 (6.7%–11.3%) at 6-mm intervals were misclassified as lesions meeting the curative resection criteria due to the underestimation of submucosal or LVI.
Conclusions
After ESD, the 2-mm wide section interval was suitable for the pathological evaluation of focal submucosal or LVI. Thus, if an EGC lesion meets the expanded criteria for the ESD specimen pathological evaluation, it could be safely followed up.
9.Non-exposure Simple Suturing Endoscopic Full-thickness Resection with Sentinel Basin Dissection in Patients with Early Gastric Cancer: the SENORITA 3 Pilot Study
Bang Wool EOM ; Chan Gyoo KIM ; Myeong-Cherl KOOK ; Hong Man YOON ; Keun Won RYU ; Young-Woo KIM ; Ji Yoon RHO ; Young-Il KIM ; Jong Yeul LEE ; Il Ju CHOI
Journal of Gastric Cancer 2020;20(3):245-255
Purpose:
Recently, non-exposure simple suturing endoscopic full-thickness resection (NESSEFTR) was developed to prevent tumor exposure to the peritoneal cavity. This study aimed to evaluate the feasibility of NESS-EFTR with sentinel basin dissection for early gastric cancer (EGC).
Materials and Methods:
This was the prospective SENORITA 3 pilot. From July 2017 to January 2018, 20 patients with EGC smaller than 3 cm without an absolute indication for endoscopic submucosal dissection were enrolled. The sentinel basin was detected using Tc 99m -phytate and indocyanine green, and the NESS-EFTR procedure was performed when all sentinel basin nodes were tumor-free on frozen pathologic examination. We evaluated the complete resection and intraoperative perforation rates as well as the incidence of postoperative complications.
Results:
Among the 20 enrolled patients, one dropped out due to large tumor size, while another underwent conventional laparoscopic gastrectomy due to metastatic sentinel lymph nodes. All NESS-EFTR procedures were performed in 17 of the 18 other patients (94.4%) without conversion, and the complete resection rate was 83.3% (15/18). The intraoperative perforation rate was 27.8% (5/18), and endoscopic clipping or laparoscopic suturing or stapling was performed at the perforation site. There was one case of postoperative complications treated with endoscopic clipping; the others were discharged without any event.
Conclusions
NESS-EFTR with sentinel basin dissection is a technically challenging procedure that obtains safe margins, prevents intraoperative perforation, and may be a treatment option for EGC after additional experience.
10.Clinical Practice Guideline for Endoscopic Resection of Early Gastrointestinal Cancer
Chan Hyuk PARK ; Dong-Hoon YANG ; Jong Wook KIM ; Jie-Hyun KIM ; Ji Hyun KIM ; Yang Won MIN ; Si Hyung LEE ; Jung Ho BAE ; Hyunsoo CHUNG ; Kee Don CHOI ; Jun Chul PARK ; Hyuk LEE ; Min-Seob KWAK ; Bun KIM ; Hyun Jung LEE ; Hye Seung LEE ; Miyoung CHOI ; Dong-Ah PARK ; Jong Yeul LEE ; Jeong-Sik BYEON ; Chan Guk PARK ; Joo Young CHO ; Soo Teik LEE ; Hoon Jai CHUN
Clinical Endoscopy 2020;53(2):142-166
Although surgery was the standard treatment for early gastrointestinal cancers, endoscopic resection is now a standard treatment for early gastrointestinal cancers without regional lymph node metastasis. High-definition white light endoscopy, chromoendoscopy, and image-enhanced endoscopy such as narrow band imaging are performed to assess the edge and depth of early gastrointestinal cancers for delineation of resection boundaries and prediction of the possibility of lymph node metastasis before the decision of endoscopic resection. Endoscopic mucosal resection and/or endoscopic submucosal dissection can be performed to remove early gastrointestinal cancers completely by en bloc fashion. Histopathological evaluation should be carefully made to investigate the presence of risk factors for lymph node metastasis such as depth of cancer invasion and lymphovascular invasion. Additional treatment such as radical surgery with regional lymphadenectomy should be considered if the endoscopically resected specimen shows risk factors for lymph node metastasis. This is the first Korean clinical practice guideline for endoscopic resection of early gastrointestinal cancer. This guideline was developed by using mainly de novo methods and encompasses endoscopic management of superficial esophageal squamous cell carcinoma, early gastric cancer, and early colorectal cancer. This guideline will be revised as new data on early gastrointestinal cancer are collected.

Result Analysis
Print
Save
E-mail